Tag Archives: Lingo

Structure’s Topline Ph2 Aleniglipron Data; Ascletis Reports Topline Data from Ph1 Oral GLP-1RA; BI Advances Triple Agonist for Obesity; Wave Announces Ph1 Data from Muscle-Sparing Asset; Lingo Now Available on Android; Medtronic Shifts Exec to MiniMed

A series of cardio-metabolic-related news items has been observed from Structure Therapeutics, Ascletis Pharma, Boehringer Ingelheim, Wave Life Sciences, Abbott, and Medtronic. Below, FENIX provides highlights and insights for the respective news items.

This content is for Read Less members only.
Register
Already a member? Log in here

Terns Discontinues Obesity Program; Lingo Available at Walmart; Roche Partners For CVRM Manufacturing; Biocon Expands US Glargine Partnership; NewAmsterdam Registers Ph3 Study of Obicetrapib FDC and Monotherapy

A series of cardiometabolic-related news items has been observed from Terns Pharmaceuticals, ROVI/Roche, Biocon/Civica, Abbott, and NewAmsterdam Pharma. Below, FENIX provides highlights and insights for the respective news items.

This content is for Read Less members only.
Register
Already a member? Log in here

FDA and EMA Implement Anti-Compounding Measures; Novo and Novonesis Partner for Gut Microbiome Research; Lexicon Submits Additional Sota T1DM Data; Lingo Sponsors US Open Coverage; Hansoh Initiates Ph3 T2DM Program of Olatorepatide in China

A series of cardiometabolic-related news items has been observed from FDA/EMA, Novo Nordisk/Novonesis, Lexicon Pharmaceuticals, Abbott, and Hansoh Pharmaceuticals. Below, FENIX provides highlights and insights for the respective news items.

This content is for Read Less members only.
Register
Already a member? Log in here

Lilly Terminates Two Naperiglipron Studies; Lingo Advertisement on Reddit; Serena Williams Becomes Ro Ambassador; Another Novo Executive Steps Down; Esperion Embraces EU Recommendations for Bempedoic Acid; Daiichi Unveils Development of Fixed-Triple Combination Tablet for Lowering LDL-C

A series of cardiometabolic-related news items has been observed from Lilly, Abbott, Ro, Novo Nordisk, Esperion, and Daiichi Sankyo. Below, FENIX provides highlights and insight for the respective news items.

This content is for Read Less members only.
Register
Already a member? Log in here

Abbott Q1 ’25 Earnings Update 

Abbott hosted its Q1’25 earnings call (press release; infographic). Of note, there was minimal discussion of Abbott’s CGM business in prepared remarks and no questions from analysts during Q&A. Abbott’s CEO Rob Ford specifically stated, “I found it interesting we did not get a single Libre question, so you guys are very concerned on tariffs and macro…” Below, FENIX provides brief highlights and insights from the call.

This content is for Read Less members only.
Register
Already a member? Log in here

Abbott Q4 ‘24 Earnings; Esperion KOL Event

Two cardiometabolic-related news items have been observed: Abbott hosted its Q4 ‘24 earnings call (press release; infographic) and Esperion hosted a virtual Nexletol KOL event (view slides). Below, FENIX provides highlights and insights for the respective news items.

This content is for Read Less members only.
Register
Already a member? Log in here

Abbott Launches Lingo OTC CGM in the US

Abbott announced Lingo, its OTC CGM, is now available for purchase in the US via its website (view website). The launch announcement comes shortly after Dexcom announced the launch of its own Stelo OTC CGM (previous FENIX insight). Below, FENIX has conducted an analysis of the Lingo product, website, and pricing.

This content is for members only.
Register
Already a member? Log in here

Abbott and Novartis Q2 ’24 Earnings

Two cardiometabolic-related news items have been observed: Abbott (press release; infographic) and Novartis (press release; slides) hosted their respective Q2 ’24 earnings calls. Below, FENIX provides highlights and insights about the respective items.

This content is for Read Less members only.
Register
Already a member? Log in here

FDA Clears Abbott’s Lingo and Libre Rio CGMs; Lilly Publishes SYNERGY-NASH Results; Teladoc Appoints New CEO

Three cardiometabolic-related news have been observed: Abbott announced FDA cleared its Lingo and new “Libre Rio” CGM systems for OTC (view press release); Lilly announced detailed results from the Ph2 SYNERGY-NASH trial were presented at EASL 2024 (June 5-8; Milan, IT) and published in the NEJM (view press release); and Teladoc appointed Charles Divita, III, as its CEO effective immediately (view press release). Below, FENIX provides highlights and insights for the respective news items, including thoughts on how Lingo and Libre Rio will compete with Dexcom’s Stelo.

This content is for Read Less members only.
Register
Already a member? Log in here